Table 2.

Uni- and multivariable analysis of prognostic factors for OS2.

	N (N of events)	mOS2 (95% CI)	HR univariable analysis	HR multivariable analysis
			(95% CI), p	(95% CI), p
Total cohort	167 (163)	5.2 (4.7–5.7)
Gender
Female	77 (75)	5.2 (4.5–5.9)
Male	90 (88)	5.1 (4.2–6.0)	1.24 (0.90–1.70) p = 0.190
Age
0–67 years	82 (79)	5.2 (4.3–6.1)
>67 years	85 (84)	5.1 (4.5–5.7)	1.16 (0.85–1.58) p = 0.362
Tumor spread
Locally advanced	22 (22)	9.4 (5.2–13.7)
Metastatic	145 (141)	4.9 (4.3–5.6)	1.42 (0.90–2.23) p = 0.129
ECOG PS
0–1	95 (91)	5.8 (4.2–7.3)
>1	27 (27)	4.2 (3.2–5.1)	1.94 (1.24–3.04) p= 0.003	1.55 (0.79–3.02) p = 0.202
CA 19–9 (kU/L)
0–1,550	52 (51)	8.5 (5.7–11.3)
>1,550	51 (50)	4.7 (3.3–6.2)	2.39 (1.55–3.68) p< 0.001	2.03 (1.19–3.46) p= 0.009
Albumin (g/L)
<35	64 (64)	4.0 (3.4–4.7)
35–47	77 (74)	7.5 (5.1–9.9)	0.39 (0.27–0.57) p< 0.001	0.21 (0.11–0.40) p< 0.001
Regimen 1st line
Monotherapy	79 (78)	7.0 (5.3–8.6)
Combination therapy	88 (85)	8.7 (7.0–10.4)	0.81 (0.59–1.10) p = 0.172
Regimen 1st line
Gemcitabine	70 (69)	6.2 (4.8–7.7)
Gem/NabP	46 (44)	9.2 (6.3–12.1)	0.70 (0.48–1.03) p = 0.067
Regimen 2nd line
Monotherapy	68 (66)	4.8 (3.7–5.9)
Combination therapy	99 (97)	5.4 (4.5–6.3)	0.79 (0.57–1.08) p = 0.135
Regimen 2nd line
Cap or 5-FU/FA	51 (49)	4.1 (2.9–5.4)
Cap/Ox or 5-FU/FA/Ox	66 (65)	5.3 (4.7–5.9)	0.88 (0.73–1.07) p = 0.189
TTF1 (months)
0–3.65	83 (81)	4.7 (3.5–5.9)
>3.65	83 (81)	5.4 (4.8–5.9)	0.84 (0.61–1.14) p = 0.253

mOS2, Median overall survival in months from start of second line treatment; HR, Hazard ratio; CI, Confidence interval; ECOG PS, Eastern Cooperative Oncology Group performance status; Gem/NabP, gemcitabine plus nab-paclitaxel; Cap, capecitabine; 5-FU/FA, 5-flourouracil plus folinic acid; Cap/Ox, capecitabine plus oxaliplatin; 5-FU/FA/Ox, 5-flourouracil, folinic acid, and oxaliplatin; TTF1, Time to treatment failure under first line treatment. All p values < 0.05 are typed in bold.